NCT02262143View on ClinicalTrials.gov

Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

362

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

June 30, 2017

Conditions
Mixed Dyslipidemias
Interventions
DRUG

Rosuvastatin

Rosuvastatin 10 mg, qd, po

DRUG

Fenofibrate

Fenofibrate 160mg, qd, po

Trial Locations (1)

Unknown

Ildong Pharm., Seoul

Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT02262143 - Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia | Biotech Hunter | Biotech Hunter